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CDKN2A and MC1R Mutations in Patients with Sporadic Multiple
Primary Melanoma
To the Editor:
The development of sporadic multiple primary melanoma
(MPM) has been correlated with an underlying genetic
susceptibility and/or exposure to UV light. To date, high-
penetrance genes such as CDKN2A and CDK4, and low-
penetrance genes such as MC1R have been shown to
contribute to melanoma predisposition. The CDKN2A (or
INK4A/ARF) locus at chromosome 9p21 encodes two alter-
natively spliced proteins, p16INK4A and p14ARF, that demon-
strate tumor suppressor activity and function as cell cycle
inhibitors (Sharpless and Chin, 2003). CDKN2A mutations
have been detected in 9%–15% of patients with MPM
(Hayward, 2003); a family history of melanoma has been
documented in many such cases. Germline mutations of
CDKN2A affecting p14ARF, however, have not been found in
patients with sporadic MPM (Auroy et al, 2001). A low
frequency of mutations of the CDK4 oncogene has been
shown in familial and sporadic melanoma (Goldstein et al,
2002), and no alterations have been detected in patients
with MPM (Auroy et al, 2001). The MC1R gene encodes
a seven-pass G-protein-coupled receptor that binds to the
a-melanocyte-stimulating hormone causing a switch from
red/yellow pheomelanin to brown/black eumelanin (Rees,
2000). Specific MC1R allelic variants (R142H, R151C,
R160W, and D294H) have been associated with fair skin
type and hair color (Valverde et al, 1996; Healy et al, 2000;
Sturm, 2002) and an increased predisposition to melanoma
development (Palmer et al, 2000; Kennedy et al, 2001).
In order to assess the presence of an underlying genetic
susceptibility to the development of sporadic MPM, we
screened 14 patients with MPM and no family history of the
disease for germline and somatic CDKN2A mutations and
for germline mutations in the p14ARF-specific exon 1b of the
CDKN2A gene, exon 2 of the CDK4 gene and the entire
coding region of MC1R gene.
The experiments conducted in this study were done in
accordance with Helsinki principles and had the Ethical
Committees’ approval. Genomic DNA was isolated from
peripheral blood using standard procedures. Tumor DNA
and DNA from nontumorous tissue were extracted following
microdissection from formalin-fixed, paraffin-embedded
tissue sections as previously described (Peris et al, 1995).
We used PCR amplification and DNA sequencing to screen
genomic DNA and DNA isolated from tumor and nontumor-
ous tissue samples for germline mutations in exons 1a, 1b,
2 and 3 of the CDKN2A gene, exon 2 of CDK4, and the
entire coding region of MC1R. PCR primers were as
previously reported for CDKN2A (Fargnoli et al, 1998)
(GenBank accession numbers: U12818, U12819, U12820),
p14ARF-specific exon 1b (Mao et al, 1995) (GenBank
accession number: L41934), and CDK4 (Zuo et al, 1996)
(GenBank accession number: U37022). PCR primers for the
MC1R gene (GenBank accession number: AF153431) were
the following: 1F-50CAACGACTCCTTCCTGCTTC30 1R-50-
GTCACGATGCTGTGGTAGC30; 2F-50ACCTGCAGCTCCAT-
GCTGTC30; 2R-50TGCCCAGCACACTTAAAGC30, and PCR
cycling conditions were: 951C for 5 min, 35 cycles of 951C
for 1 min, 551C for 1 min and 721C for 1 min followed by a
final extension step at 721C for 7 min. Sequencing of the
gel-purified PCR products was performed with the same
primers used for PCR amplification and the ABI Prism
BigDye Terminator Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, California). Automated sequencing was
carried out with the ABI Prism 377 DNA sequencer.
To examine somatic alterations, loss of heterozygosity
(LOH) and microsatellite instability (MSI) analyses at
D9S974, D9S171, D9S126 were performed as previously
reported (Peris et al, 1999). In cases in which LOH was
found at 9p21, sequencing analysis of the CDKN2A gene
was performed as described (Peris et al, 1999).
The study population consisted of 14 patients with MPM
and no family history of melanoma (nine males and five
females, with a mean age at the time of the first melanoma
diagnosis of 46.9 y; range: 26–78 y). Phenotypic character-
istics of the patients are reported in Table I. In eight patients,
the melanomas were synchronous. In the remaining six
patients, the diagnosis of the second melanoma was made
between 1 and 8 y (mean: 4 y) after diagnosis of the first
melanoma. Twenty-eight of 44 paraffin-embedded melanoma
samples were available for analysis of somatic alterations.
Germline CDKN2A mutations were found in three of 14
(21.4%) MPM patients: two patients carried an ISV2þ
1G4A mutation whereas the third patient harbored the
G101W mutation (Fig 1, Table I). No germline CDKN2A
mutations were identified in exon 1b, encoding the p14ARF
protein.
LOH at D9S974 was found in two of seven melanoma
tissues of the patient (no. 14) who carried the G101W
mutation. LOH at D9S171 in one allele and a 51_52insC at
exon 1a in the second allele were detected in one of four
melanomas from a patient (no. 11) who did not carry
germline CDKN2A mutations (Fig 1, Table I). The 51_52insC
mutation creates a frameshift and introduces a premature
stop at codon 25, resulting in a truncated p16INK4A protein.
No mutations were detected in exon 2 of the CDK4 gene
in any of the 14 patients examined.Abbreviation: MPM, multiple primary melanoma
Copyright r 2004 by The Society for Investigative Dermatology, Inc.
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Mutational analysis of MC1R gene was performed in 12
patients because DNA samples from the remaining two
patients were no longer available. Seven MC1R allelic
variants (V60L, V92M, T95M, R142H, R151C, R160W, and
86_87insA) were detected in 11 of 12 (91.7%) patients. Two
patients (nos. 3 and 9) with germline MC1R mutations also
carried the ISV2þ 1G4A CDKN2A mutation (Table I).
In a series of MPM patients with a negative family history
of melanoma, MacKie et al (1998) identified CDKN2A
alterations in two of the 17 patients screened, one of whom
harbored the ISV2þ1G4T mutation. Rutter et al (2003)
recently demonstrated that this mutation reveals a cryptic
splice site within exon 2 and also causes complete skipping
of exon 2, resulting in the dual inactivation of p16INK4A and
p14ARF. In our study, a novel ISV2þ 1G4A CDKN2A
mutation was detected in two of 14 patients with sporadic
MPM. The effects of this mutation on splicing and on
p16INK4A and p14ARF function needs to be characterized.
The third patient in our series with a germline CDKN2A
mutation had G101W, which represents a well-known
founder effect in melanoma families with a French, Italian,
and American background (Ciotti et al, 2000). Recently, a
common haplotype was also found in patients with sporadic
MPM carrying the G101W mutation, further indicating that
G101W is a common founder mutation (Auroy et al, 2001). In
the absence of haplotype analysis in our patient and his
relatives, we cannot exclude the possibility of this mutation
representing a founder effect.
A single germline mutation (60ins16) in exon 1b of the
CDKN2A gene has been detected in a patient with sporadic
MPM (Rizos et al, 2001). In our study, no mutations affecting
p14ARF were identified in patients with MPM, supporting the
hypothesis that the p14ARF might play a pathogenetic role in
only a minority of melanomas.
The lack of activating mutations at exon 2 of the CDK4
gene, as detected in our series and in a previous report
(Auroy et al, 2001), suggests that CDK4 alterations may not
be as prevalent in melanoma as originally thought.
Recent studies have demonstrated that specific MC1R
variants act as modifier alleles, increasing the raw pene-
trance of CDKN2A mutations in Australian and Dutch
melanoma kindreds (Box et al, 2001; van der Velden et al,
2001). We detected seven MC1R variants in 11 of 12
(91.7%) patients with sporadic MPM, which represents a
much higher frequency as compared with that previously
reported in other populations (Sturm et al, 2001). Three of
the 11 MPM patients who carried MC1R allelic variants
suffered the highest number of MPM and had red hair.
Notably, two of these red heads were also CDKN2A
mutation positive. Thus, our results might suggest another
example of the effects of gene–gene interaction on disease
risk.
In conclusion, we demonstrated that CDKN2A germline
mutations may contribute to melanoma susceptibility in
certain MPM patients and that MC1R allelic variants are
frequent in such patients.
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Figure 1
Germline and somatic CDKN2A muta-
tions in patients with sporadic multiple
primary melanoma (MPM). (A) Direct
automated sequencing of germline
CDKN2A in patient no. 9. (a) Wild-type
DNA sequence and (b) G>A substitution
at the splice donor site in exon 2. (B)
Germline and somatic CDKN2A mutations
in patient no. 14. (a) Germline wild-type
DNA sequence (top) and C4T transition
at base 301 in exon 2 (bottom); (b) loss of
heterozygosity (LOH) at microsatellite
marker D9S974, as indicated by arrow,
was observed in melanomas T5 and T6 as
compared with nontumorous tissue from
the same patient; (C) Double somatic
CDKN2A mutations in the absence of
germline mutations in patient no. 11. (a)
LOH at D9S171 (arrow) in Allele 1; (b)
wild-type CDKN2A sequence (top) and a
C insertion at nucleotide 51_52 (arrow)
exon 1a in allele 2 (bottom).
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